|
Federal Circuit finds prosecution history disclaimer in enablement arguments
Lexology (registration) The specification describes Biogen’s product Rituxan® (rituximab) as a preferred embodiment. Rituximab binds to a large loop of the CD20 protein that is exposed on the cell surface. This loop constitutes the particular “epitope” recognized by the … |
EPOCH-Rituximab Therapy Obviates Need for Radiotherapy in B-Cell LymphomaCancer NetworkA dose-adjusted regimen of etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) obviated the need for radiotherapy i…
|
Enrollment for Pharmacyclics’ Phase III study using ibrutinib in CLL patients …
News-Medical.net … planned 110 patients in the Phase II single-arm study using ibrutinib in patients with mantle cell lymphoma (MCL) who progress after bortezomib therapy and have received at least one prior rituximab-containing chemotherapy regimen, SPARK (MCL2001). |
Patients with chronic fatigue use additional areas of brain when using memoryHealthCanal.comThese include, why some patients experience significant pain that is unresponsive to pain killers; whether using a monoclonal antibody (Rituximab), which is hig…
Pharmacyclics completes enrollment in phase III Ibrutinib CLL studypharmabiz.com… planned 110 patients in the phase II single-arm study using ibrutinib in patients with mantle cell lymphoma (MCL) who progress after bortezomib therapy and have receive…
PCYC Completes RESONATE EnrollmentZacks.com… which is being conducted to evaluate ibrutinib in mantle cell lymphoma (MCL) patients whose disease has progressed even after having received Velcade (bortezomib) therapy and at least one prior Rituxan (ri…
|
Celltrion slides to third in race for Roche rituximab biosimilar with planned …
Financial Times Celltrion, (KOSDAQ: 068270) the South Korean biosimilars developer, now looks to be third in the race to develop a biosimilar version of Roche’s (VTX:ROG) blockbuster Rituxan/Mabthera (rituximab), after it has emerged it does not actually plan to start … Report: Don’t count Celltrion out of Rituxan biosim raceFierceBiotech |
Presage Biosciences Announces First Patient in Clinical Trial of CIVO(TM …Wall Street JournalThe trial will enroll up to 12 patients with either newly diagnosed lymphomas who have not yet received treatment or relapsed lymphoma previously treated wit…
Roche sees another Rituxan biosimilar bite the dustFierceBiotechSamsung Electronics and Teva Pharmaceutical ($TEVA) both bailed out on biosimilar versions of rituximab (MabThera/Rituxan) last year amid uncertainty in regulation of copycat biologics in …
|
Biogen Idec, Inc. v. GlaxoSmithKline LLC (Fed. Cir. 2013)
Patent Docs The examiner acknowledged that the specification was enabling for Biogen’s chimeric gamma 1 anti-human CD20 antibody, Rituxan® (rituximab), but was silent concerning the specificity and affinity that would be necessary for other anti-CD20 antibodies. |